AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06544278 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: During the experiment, subjects take one sachet maltodextrin daily with 3.0g. Evaluation is conducted by monitoring the subjects' semen concentration before and after this trial.
Study NCT05939297 — intervention group
Intervention type: OTHER
Intervention: Heart Health Self-efficacy and Self-Management Scale
Description: In order to measure the self-management and self-efficacy levels of the individuals, patients will be administered the Heart Health Self-efficacy and Self-Management Scale.
Study NCT05939297 — intervention group
Intervention type: OTHER
Intervention: Self-Care Management Scale in chronic diseases
Description: For the external construct validity statistical method, the self-management level of the individuals will also be determined with the Self-Care Management in Chronic Diseases Scale, which has been previously validated and reliable in Turkish.
Study NCT05939297 — intervention group
Intervention type: OTHER
Intervention: general self-efficacy scale
Description: For the external construct validity statistical method, the self-efficacy level of the individuals will also be determined with the general self-efficacy scale, which has been previously validated and reliable in Turkish.
Study NCT06297252 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: standardized clinical psychiatric evaluations
Description: The intervention consists of a psychiatric consultation including :~* assessment of psychiatric disorders using a MINI test~* information gathering (medical, obstetrical and family history, expected term of pregnancy).~* assessment of suicidal behaviour using the Columbia-Suicide Severity Rating Scale (CSSR-S)~* collection of negative life events over the past 12 months, assessed using the Paykel questionnaire
Study NCT06297252 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: self-administered psychiatric questionnaire assessments
Description: * EPICES Score: (Evaluation de la Précarité et des Inégalités de santé dans les Centres d'Examens de Santé):~* MIBS: (Mother to Infant Bonding Scale)~* PAI: (Prenatal Attachment Inventory)~* EDEQ: (Eating Disorder Examination Questionnaire)~* PCL-5: (Post-traumatic Stress Disorder Checklist for DSM-V)~* MARS: (Medication Adherence Rating Scale)~* EPDS: (Edinburgh Postnatal Depression Scale)
Study NCT06297252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: A blood sample is taken to form an optional biological collection, comprising 3 samples:~* A tube to collect RNA from whole blood.~* A tube to collect serum~* A tube to collect native DNA
Study NCT05258370 — intervention group
Intervention type: OTHER
Intervention: Dosage
Description: Evaluation of circulating C-terminal FGF23 (FGF23Ct) rate, circulating intact FGF23 (FGF23i) rate and Erythropoietin
Study NCT05258370 — intervention group
Intervention type: OTHER
Intervention: Cardiac echography
Description: 12 months after patient enrollment
Study NCT04897867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoolSculpting® Elite System with CoolSculpting® Elite applicators
Description: A treatment session is comprised of timed segments of cooling (treatment cycles) followed by 2 minutes of manual massage.
Study NCT05329116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2% Injectable Solution
Description: Patients will be administered 1.5 ml of 2% lidocaine, 1.5 ml of 30 mg of pentoxifylline.~Among the injection techniques, profundal intradermic injection (IDP, injection depth: 2-4 mm) and superficial intradermic injection (IDS, injection depth: 1-2 mm) will be used.~8 mL of peripheral blood will be taken from the patient and centrifuged at 4000 rpm for 8 minutes. Then, 3-4 mL of PRP will be taken and used for intra-articular injection
Study NCT05329116 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-rich plasma
Description: 8 mL of peripheral blood will be taken from the patient and centrifuged at 4000 rpm for 8 minutes. Then, 3-4 mL of PRP will be taken and used for intra-articular injection
Study NCT04990921 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Palliative Radiation and Pembrolizumab
Description: Stereotactic radiation therapy will be administered as clinically indicated.
Study NCT04600167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid and Rifapentine (INH-RPT)
Description: Oral combination of rifapentine (RPT, 900 mg) and isoniazid (INH, 900 mg), once-weekly for 12 weeks.
Study NCT04600167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the control group will receive placebo once weekly for 12 weeks
Study NCT05804799 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast-enhanced liver CT scan
Description: The contrast-enhanced liver CT scans were obtained from all of the participants.~The liver CT images were reconstructed by both low-dose scans with a deep-learning-based denoising program (ClariCT.AI) and standard-dose scans with model-based iterative reconstruction.
Study NCT06151392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Formula
Description: probiotic will be administered to pediatric patients with ventriculitis to study their possible effect in treatment
Study NCT06151392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc
Description: Zinc will be administered to pediatric patients with ventriculitis to study their possible effect in treatment
Study NCT05233358 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic Artery Infusion Chemotherapy
Description: HAIC adopts FOLFOX chemotherapy regimen, hepatic arteriography through a radial artery or femoral artery cannulation, routine hepatic artery cannulation, imaging, infusion of chemotherapy drugs into hepatic artery: oxaliplatin 85 mg/m2 on the first day for 0-3 hours, folinic acid 400 mg/m2 for 3-4.5 hours on day 1, fluorouracil 400 mg/m2 for 4.5-6.5 hours on day 1, and fluorouracil 2500 mg/m2 for 46 hours on days 1-3.
Study NCT05233358 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial Chemoembolization
Description: Treatment regimens have chosen lipiodol-based hepatic arterial chemoembolization, with lipiodol dosage varying from 5-20ml depending on tumor size. The chemotherapy drug is gemcitabine 1.0 combined with 100mg oxaliplatin, combined with 1/3 to 1 dose of solid embolic agent (the dosage is determined by the investigator based on the tumor size). After uniform emulsification, the drug is injected into the supplying blood vessels and stops when the intravascular blood flow is slow. Later, angiography is performed again, and the tumor staining disappears and the supplying artery is occlusions.~CT or MRI scans are performed 4 to 6 weeks postoperatively to assess the presence of active lesions. Repeat TACE if active lesions are still present. The frequency of TACE treatment is determined by the investigator and is given according to the patient's condition, generally 2-4 times. The interval between TACE treatments is 30-45 days, with a maximum of six cycles.
Study NCT05233358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib is administered for 28 days per treatment cycle, with oral regorafenib on days 1-21, 80-160 mg once daily. The dose is adjusted according to adverse reactions, with a minimum of 80 mg.
Study NCT05233358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: Regorafenib is administered for 28 days per treatment cycle, with oral regorafenib on days 1-21, 80-160 mg once daily. The dose is adjusted according to adverse reactions, with a minimum of 80 mg.
Study NCT05233358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Checkpoint Inhibitors
Description: Optional immune checkpoint inhibitors include Camrelizumab, Sintilimab, Nivolumab, Pembrolizumab, and Toripalimab. Treatment is based on the immune checkpoint inhibitor before the patients are randomized into the group, and it is not recommended to replace the immune checkpoint inhibitor. The dosage is 200 mg, intravenous infusion, D1, once every 21 days (Q3W). Dosing interruption or dose reduction may be necessary based on individual safety and tolerability considerations; dosing with immune checkpoint inhibitors should not be suspended for more than 4 weeks.
Study NCT05233358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immune Checkpoint Inhibitors
Description: Optional immune checkpoint inhibitors include Camrelizumab, Sintilimab, Nivolumab, Pembrolizumab, and Toripalimab. Treatment is based on the immune checkpoint inhibitor before the patients are randomized into the group, and it is not recommended to replace the immune checkpoint inhibitor. The dosage is 200 mg, intravenous infusion, D1, once every 21 days (Q3W). Dosing interruption or dose reduction may be necessary based on individual safety and tolerability considerations; dosing with immune checkpoint inhibitors should not be suspended for more than 4 weeks.
Study NCT05123235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: the participants will be encouraged to set their own physical activity goals weekly and using behavioral strategies work towards meeting those goals. The behavioral strategies will be discussed weekly for 30 minutes a telehealth method.
Study NCT05642377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGR4113
Description: Once-daily oral administration
Study NCT05642377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily oral administration
Study NCT05642377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGR4113
Description: Twice-daily oral administration
Study NCT05642377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice-daily oral administration
Study NCT06322082 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The DUOLITH SD1-TOP focused shock wave system (STORZ MEDICAL AG)
Description: The LiESWT was applied to Pilates and Shock Wave group and Shock Wave group with 0.25 mJ/mm2 of intensity, 3000 pulses of shock, and 3 pulses/s of frequency, applicator was placed on the suprapubic skin area one session in the week for twelve weeks, totaling 12 sessions.~Pilates exercises were performed to Pilates and Shock Wave group and Pilates group. The sessions of Pilates were applied twice a week for twelve weeks, totaling 24 sessions. The 50 min Pilates sessions were divided into three phases: warm-up, strengthening, and stretching. They also received written orientations to perform three exercises and two of the Pilates session at home every day - Conventional pelvic floor exercises performed for all groups include Kegel exercise, squats, bridging, and squeeze and release exercises. These exercises were performed 3 times per day, lasting for 12 consecutive weeks
Study NCT04772248 — intervention group
Intervention type: DRUG
Intervention: Tofacitinib
Description: First eligible prescription for treating rheumatoid arthritis (RA)
Study NCT04772248 — intervention group
Intervention type: DRUG
Intervention: TNF Inhibitor
Description: First eligible prescription for treating rheumatoid arthritis (RA)
Study NCT05088473 — intervention group
Intervention type: OTHER
Intervention: Biological collection
Description: Collection of cerebrospinal fluid kappa and lambda free light chains and indexes
Study NCT05249335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OST
Description: The subject will receive Orafang for colonoscopy
Study NCT05249335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2L-PEG/Asc
Description: The subject will receive 2L-PEG/Asc for colonoscopy
Study NCT04937101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine-Codeine
Description: When the filter tester is sensitive, he opened the random letter group envelope to the notification letter manager and jointly confirmed the classification of the message group. The test group used the chlorpheniramine beacon, the physiological surface was used, and the local lesions of fine particles were used in the focus. Injection therapy. No form of anesthesia is used during injection. A total of injection treatment, at intervals, each treatment and the last treatment, treatment and safety after 1 month.
Study NCT04465136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CES, Alpha-Stim stimulator (Electromedical Products International, Inc., Mineral Wells, Texas, USA)
Description: CES is a brain stimulation device with 2 electrodes on the bilateral earlobe. It uses Alternating current to stimulate the brain including thalamus, vagus nerve system and influence EEG and neurotransmitters like gamma-aminobutyrate. Stimulation was applied at a current intensity that can be adjusted continuously to provide between 10 and 600 micro-ampere and frequency of 0.5Hertz for 60 minutes, everyday for 6 weeks, total 42 sessions.
Study NCT06200025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cue-based speech therapy in virtual reality
Description: Treatment applied with virtual reality headsets to provide 3d visual and auditory cues to individuals in a virtual environment. A treatment environment where the provision of cues can be controlled by the therapist, interacting with 3d clues and receiving feedback on the accuracy of the named objects.
Study NCT06200025 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cue-based speech therapy
Description: Treatment involving the assessment of language skills and the presentation of communication strategies to the individual, including the use of personalized phonological cues.
Study NCT04196114 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STIMO-2 device implantation
Description: Implantation of SCS lead in epidural space and implantation of neurostimulator in abdominal region
Study NCT05488860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide(scar)/5-ALA(others)
Description: For scar, the drug is triamcinolone acetonide.
Study NCT05488860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezoelectric drived microneedling
Description: Piezoelectric drived microneedling
Study NCT05488860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-ALA (a photosensitizer for photodynamic therapy).
Description: For other diseases, the drug is 5-ALA (a photosensitizer for photodynamic therapy).
Study NCT06455982 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: reduced carbohydrate menu combined with ketogenic supplement
Description: Participants will eat a reduced carb menu for 2 months and they will take 15g of MCT in the morning and the evening for a total of 30g per day.
Study NCT05137184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Description: Inhalation of Methoxyflurane
Study NCT05137184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Intranasal Fentanyl
Study NCT05137184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine hydrochloride
Description: Intravenous Morphine
Study NCT05880056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerkardou (5 mg) & (10 mg)
Description: Bisoprolol oral dissolved film ODF(5 mg): equivalent to 5 mg of bisoprolol fumarate Bisoprolol oral dissolved film ODF (10 mg): equivalent to 10 mg of bisoprolol fumarate.
Study NCT06562023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Patients will receive BTA injection within a period of 5 days after primary closure.
Study NCT06562023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mesotherapy
Description: Patients will receive mesotherapy growth factor serum with a derma pen within a period of 5 days after primary closure.
Study NCT06560580 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 3% Diquafosol Sodium Eye Drops
Description: Each patient was prescribed 3% (5 mL: 150 mg) diquafosol sodium eye drops \[Diquas®, provided by Santen Pharmaceutical (China) Co., Ltd.\], recommended to instill one drop six times daily for 3 months. Follow-up examinations were conducted at baseline, 1 month, and 3 months after treatment initiation.
Study NCT06561100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sub-symptomatic Adaptable Exercise Treatment (SAET)
Description: Each workout will be structured in a similar format. The first 5 minutes will be devoted to stretching and warm up exercises. Then the next 20 minute segment devoted to light to moderate aerobic exercise. The second 20 minutes of each exercise session will be composed of a series of 5 predetermined exercises that rotate every day. Each workout will have one or two alternatives that the patient can complete either for modification to accommodate a physical limitation or to optimize preference. Resistance training each day will include multi-joint functional movements along with stability work. The last five minutes of the session will include more mobility work, and/or cooling down.
Study NCT05232409 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zeaxanthin
Description: The doses of zeaxanthin will be based on weight starting with 2 milligrams of zeaxanthin per kilogram of your body weight (mg/kg) followed by 4 mg/kg, 6 mg/kg, and finally 8 mg/kg. If a dose level is found to be unsafe, then a new group of patients will be treated at the midpoint dose between the not tolerated dose and the last tolerated dose. Zeaxanthin is supplied as 50 milligram capsules and a person's dose will be rounded to the nearest 50 milligrams.
Study NCT05232409 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Zeaxanthin Plus Pembrolizumab
Description: The doses of zeaxanthin will be based on weight starting with 2 milligrams of zeaxanthin per kilogram of your body weight (mg/kg) followed by 4 mg/kg, 6 mg/kg, and finally 8 mg/kg. If a dose level is found to be unsafe, then a new group of patients will be treated at the midpoint dose between the not tolerated dose and the last tolerated dose. Zeaxanthin is supplied as 50 milligram capsules and a person's dose will be rounded to the nearest 50 milligrams.~The dose of pembrolizumab will be administered at a fixed dose of 400 milligrams intravenous every 6 weeks which is an FDA approved dosing schedule to treat cancer patients with pembrolizumab.
Study NCT04612608 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: upright bed
Description: moving the bed into an upright position
Study NCT05112731 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: BAFF and MGO
Description: measurement of BAFF and MGO levels before reperfusion and after 3 months
Study NCT06561100 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching Control Group (SCG)
Description: Each workout will be 50-60 minutes long and participants are instructed to not do any other type of exercise that may elevate their heart rate. Modifications will be available for stretches that may be too advanced for the individual.
Study NCT04670250 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: non invasive markers
Description: non invasive markers (IL6, serum ferritin, fecal lactoferrin) used for monitoring of newly diagnosed patients with ulcerative colitis
Study NCT05255380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and compassion-based practices; approximately 5-10 minutes two times/day
Description: The app-based (audio-guided) interventions consist of mindfulness and compassion-based practices that are selected to maximize their effect on stress targets. Interventions include, for example, practices that focus on the breath/body (e.g., 3-minute breathing space; compassionate body scan; five senses mediation), on increasing participants' inner resources (e.g., imaging a safe person or safe place), on reducing negative affect (e.g., self-compassion and acceptance-based practices), or on increasing positive emotions (e.g., gratitude practice; metta practices).
Study NCT05255380 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Mindful awareness and reporting of current thoughts and feelings, 2 times/day
Description: Participants are instructed to be mindful (pay attention) to their current thoughts and feelings and complete ecological momentary assessments of their current psychological stress states (e.g., stress appraisals, affect, perseverative cognitions, self-criticism, social connection)
Study NCT05212285 — intervention group
Intervention type: DEVICE
Intervention: Inbody 570
Description: Bioelectrical Impedance Analysis with Inbody 570 (Inbody Co., Seoul, Korea) during each follow-up
Study NCT05212285 — intervention group
Intervention type: DEVICE
Intervention: JAMAR Dynamometer
Description: Handgrip strength measurement using a JAMAR Dynamometer (JAMAR Co., Ltd., USA) during each follow-up
Study NCT05212285 — intervention group
Intervention type: RADIATION
Intervention: CT scan
Description: Chest and abdominal CT scan during each follow-up
Study NCT05980156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine
Description: Treatment will be with DP (females less than 10 years old and all males) or chloroquine alone (females 10 years old or older).
Study NCT05980156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Treatment of females 10 years old and older in Arm 1 and treatment of all participants in Arm 2.
Study NCT05980156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine pyrimethamine
Description: Treatment will be with SP and chloroquine (females less than 10 years old and all males) or chloroquine alone (females 10 years old or older).
Study NCT06347562 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Optical Genome Mapping
Description: to evaluate the capability of OGM, its usefulness in clinical diagnosis, and its impact on genetic counseling.
Study NCT04710381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMUNOR
Description: The intervention consists of the administration of IMUNOR as prevention against COVID-19 disease